Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-190X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community ; day:24 ; month:4 ; year:2017 ; pages:1-13
BioDrugs ; (24.4.2017), 1-13
- Keyword
-
Biopharmazie
Pharmakodynamik
Pharmakokinetik
- Creator
-
Markus, Richard
- Contributor
-
Liu, Jennifer
Ramchandani, Monica
Landa, Diana
Born, Teresa
Kaur, Primal
SpringerLink (Online service)
- DOI
-
10.1007/s40259-017-0218-5
- URN
-
urn:nbn:de:1111-201705066376
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
2025-08-14T10:44:46+0200
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Markus, Richard
- Liu, Jennifer
- Ramchandani, Monica
- Landa, Diana
- Born, Teresa
- Kaur, Primal
- SpringerLink (Online service)
Other Objects (12)
Pharmacovigilance Considerations for Biosimilars in the USA
Biosimilars – Biosimilars: ja, aber
Biosimilars
The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects
An Efficient Development Paradigm for Biosimilars
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?
Biosimilars : Handbuch
Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
Biosimilars : ein Handbuch
Biosimilars – Alternative wirkt
Biosimilars im Fokus : Diskussionspapier zur Substitution von Biosimilars in Apotheken
US regulatory considerations for low field magnetic resonance imaging systems
Pharmacovigilance Considerations for Biosimilars in the USA
Biosimilars – Biosimilars: ja, aber
Biosimilars
The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects
An Efficient Development Paradigm for Biosimilars
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?
Biosimilars : Handbuch
Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
Biosimilars : ein Handbuch
Biosimilars – Alternative wirkt
Biosimilars im Fokus : Diskussionspapier zur Substitution von Biosimilars in Apotheken
US regulatory considerations for low field magnetic resonance imaging systems
Pharmacovigilance Considerations for Biosimilars in the USA
Biosimilars – Biosimilars: ja, aber
Biosimilars
The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects
An Efficient Development Paradigm for Biosimilars
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?
Biosimilars : Handbuch
Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
Biosimilars : ein Handbuch
Biosimilars – Alternative wirkt
Biosimilars im Fokus : Diskussionspapier zur Substitution von Biosimilars in Apotheken